Tilray's FY26 Math: EBITDA Beats, Cash Burn Still the Question

HEADLINE

Tilray's FY26 math: EBITDA growth, but free-cash-flow gap keeps markets cautious

Tilray’s fiscal 2026 release forces a blunt accounting question for the sector: adjusted EBITDA can grow, but until it converts to positive free cash flow the equity-case remains conditional. For U.S. MSOs and cannabis ancillaries — from Green Thumb-style retailers to Curaleaf-scale platforms and POS/ancillary providers — the read-through is simple: operational leverage matters, but capital structure and cash conversion decide valuations. We anchor today’s view on Tilray’s SEC disclosures and the DEA rescheduling timeline and draw explicit read-throughs for U.S. operators and listed ancillaries.

Lede — the filings that matter today

Tilray filed its fiscal 2026 earnings release as SEC Exhibit 99.1, where management reported net revenue of $915.454 million, adjusted EBITDA of $61.139 million and reported free cash flow of negative $98.624 million for the fiscal year ended May 31, 2026. The company issued fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million and reiterated it expects more than $1 billion in annual revenue. Those figures — from the company’s SEC exhibit — remain the central, citable anchors for assessing how public cannabis operators translate growth into durable equity value. (See Tilray filing: Fiscal 2026 earnings release — SEC Exhibit 99.1.)

Parallel to company-level accounting is the regulatory backdrop. The DEA ordered transcript corrections and set post-hearing briefs due on August 17, 2026, following the June 29–July 15, 2026 administrative hearing — a procedural step that still leaves substantive timing and outcome open. The DEA order is an important systemic variable for U.S.-listed names with material U.S. exposure. (See DEA order: Proposed Marijuana Rescheduling — DEA PDF.)

Thesis — what Tilray’s disclosures imply for U.S. MSOs and ancillaries

Thesis in one line: revenue and adjusted EBITDA expansion is necessary but not sufficient — until adjusted EBITDA reliably converts to positive free cash flow and balance-sheet resiliency, equity upside remains tethered to execution and capital management.

Why this matters for U.S. MSOs and ancillaries:
- Public MSOs (names like GTBIF, CURLF, TCNNF, CRLBF, VRNOF) compete on scale and unit economics. Tilray’s ability to grow revenue toward the $1B+ mark while still reporting a near-$99M cash burn signals that margin expansion alone does not neutralize capital intensity or working-capital needs.
- Ancillary, technology and services providers — think payments, point-of-sale and loyalty platforms — face a different multiple regime: lower capital intensity but higher sensitivity to adoption and recurring revenue quality. The market’s reaction to small-cap movers in today’s tape (e.g., POSAF +13.1% on Canada/OTC tape) shows appetite for EBITDA-accretive, low-capex stories even as larger operators wrestle with cash conversion.
- Regulatory catalysts (DEA procedural moves) remain binary for how quickly addressable markets expand in the U.S.; the procedural deadline noted in the DEA order reduces uncertainty about the administrative record, but does not guarantee a rescheduling outcome favorable to commercial expansion.

Forecasts — what we’d model and monitor

We lay out forward-looking, filing-consistent metrics to track. We do not assign price targets; rather, we define the KPIs that determine whether adjusted EBITDA translates into equity value.

• Fiscal 2027 adjusted EBITDA range to monitor: the company guided $68M–$75M (Tilray SEC exhibit). Our baseline expectation: management must show sequential quarterly cash-flow improvement and at least one quarter of materially lower cash burn before the market shifts from skepticism to valuation expansion.
• Cash-position dynamics: monitor quarterly cash & equivalents and marketable securities line items versus debt maturities. Tilray reported cash & equivalents of $225.977M and $5.289M in marketable securities at May 31, 2026 (Tilray exhibit). Watch for cash-flow from operations turning positive or strategic capital raises that do not dilute existing holders beyond the thresholds management flagged in its risk disclosures.
• For U.S. MSOs: key unit-economics and free-cash-flow-per-store metrics (same-store sales, gross margin per gram, cost per extracted unit, and SG&A as a % of revenue) — relative improvements here drive adjusted EBITDA conversion into cash.

Sector read-throughs and market reaction today

Market movers on today’s tape offer micro signals:
- On the U.S. tape, penny and small-cap names saw outsized moves — MJNA spiked +100.0% on the U.S. tape and INSU jumped +29.0% — symptomatic of retail flows chasing immediate headlines, not fundamentals.
- On the Canada/OTC tape, POSAF rallied +13.14% and RVV.V slid -15.25%, the latter staying on CIN’s distressed list. Movements in ancillaries and OTC biotech-like names signal bifurcated risk appetite: investors reward perceived optionality and recurring-revenue models while punishing balance-sheet or execution risk.

These moves underscore the market’s bifurcation: scale operators are priced on cash-conversion potential, while smaller names trade on narrative and short-term liquidity.

Explicit risks — what can break the thesis

1. Continued negative free cash flow: Tilray’s FY26 free cash flow was negative $98.624M. Without demonstrable improvement, the company may need capital raises or debt refinancing that dilute equity or raise financing costs.
2. Execution on acquisitions and integrations: Tilray cited beverage acquisitions (e.g., BrewDog acquisitive context in its filings) as growth drivers — failure to integrate or achieve synergies would invalidate the EBITDA-to-cash conversion pathway (see the company’s filing context: Tilray fiscal 2026 and third-quarter filings).
3. Regulatory timing: The DEA procedural deadline for transcript corrections and post-hearing briefs (Aug 17, 2026) does not equate to a final rescheduling decision. A delayed or unfavorable federal outcome preserves current market limitations for U.S. MSOs.

How we’d lean — positioning and monitoring

• Positioning: For investors focusing on U.S. MSOs, prioritize companies with clear paths to positive free cash flow, conservative balance sheets, and recurring revenue that is less capital-intensive. For ancillaries, favor recurring-revenue models with low capex and strong customer-retention metrics.
• Monitor these filings and data points each quarter: Tilray’s Exhibit 99.1 disclosure for FY26 (linked above), the company’s subsequent SEC exhibits on integration progress, and DEA procedural releases. Specific immediate-monitor items: quarterly free-cash-flow run-rate, cash & equivalents vs near-term debt, and any management bridge from adjusted EBITDA guidance to GAAP cash generation.

Sources and anchors

• Tilray Brands fiscal 2026 earnings release (SEC Exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1731348/000117184326004944/exh_991.htm
• Tilray Brands fiscal 2026 and third-quarter earnings releases (SEC): https://www.sec.gov/Archives/edgar/data/1731348/000117184326002136/exh_991.htm
• DEA order: Proposed Marijuana Rescheduling — transcript corrections and post-hearing briefs: https://www.dea.gov/sites/default/files/2026-07/Proposed%20Marijuana%20Rescheduling_Ord%20re%20Transcript%20Corr%20and%20PHB.pdf

What we'd watch — crisp checklist

• Quarterly free cash flow improvement or one-off items explaining FY26 cash burn (Tilray’s FY26 FCF: - $98.624M).
• Confirmed bridge from fiscal 2027 adjusted EBITDA guidance ($68M–$75M) to expected GAAP operating income and free cash flow — absent this, skepticism will remain.
• DEA final administrative findings and any rapid shift in federal enforcement posture — procedural milestones (post-hearing brief deadline Aug 17, 2026) are necessary but not sufficient for policy change.

Bottom line

Tilray’s filings provide a cleaner view of sector dynamics: revenue and adjusted EBITDA expansion are real and are the market’s minimum expectation; the equity re-rating requires demonstrable cash conversion and balance-sheet durability. For U.S. MSOs and ancillaries the message is tactical — prioritize operators that can show cash-flow per unit improvement and structural balance-sheet resilience while tracking regulatory milestones closely.